NeuroCog Trials today announced it received a 2017 Fast Track grant from the NIH to study the validation of a performance-based measure of functioning in Mild Cognitive Impairment and early ALZ’s disease using NCT’s proprietary technology, the Virtual Reality Functional Capacity Assessment Tool.
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders |
| [30-October-2017] |
| DURHAM, N.C., Oct. 30, 2017 /PRNewswire/ -- NeuroCog Trials (NCT), the premiere global cognition and clinical assessment consulting and technology company, today announced it received a 2017 Fast Track grant from the National Institute of Health (NIH) to study the validation of a performance-based measure of functioning in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease (AD) using NCT’s proprietary technology, the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). The VRFCAT is a state-of-the-art solution developed to improve clinical trials by detecting functionally meaningful improvements in patient’s everyday lives. “As clinical assessment technology evolves, NCT is proud to be at the forefront of developing a modern and reliable assessment of everyday functioning,” said Richard Keefe Ph.D., Founder and Chief Executive Officer of NeuroCog Trials. “With validation data already showing the VRFCAT is a strong measure of functional capacity in schizophrenia; and with the overwhelming support from the pharmaceutical industry, we are eager to incorporate this innovative tool into clinical trials for various CNS and non-CNS disorders around the world.” As scientific consensus regarding the need for improved measurement of functional capacity increases, the VRFCAT provides an answer to the unmet demand for advanced technological solutions. Initially developed for use in patients with severe mental illness, the VRFCAT has demonstrated strong psychometric properties and has been implemented in large-scale clinical trials for schizophrenia and major depression. The NIH grant will create and validate a new version of the VRFCAT based on established standards for adapting computerized cognitive tests for new target groups. Phase I will assess the suitability of the existing VRFCAT and identify any needed software customizations. In Phase II, NCT will execute a comprehensive validation study to examine the psychometric properties of the VRFCAT-MCI to accelerate breakthrough treatments to delay, slow, and prevent AD. About NeuroCog Trials NeuroCog Trials (NCT) is a global cognition and clinical assessment services and technology company devoted to applying rigorous standards for key endpoints in multi-site clinical trials in many different indications. NCT has provided consulting, site screening, rater training and certification, translation, and data services for more than 100 clinical trials in over 25 countries. Founded in 2005, NCT is a privately held, certified woman-owned business, headquartered in Durham, North Carolina. Press Contact View original content with multimedia:http://www.prnewswire.com/news-releases/neurocog-trials-awarded-nih-grant-to-validate-performance-based-measure-of-functioning-in-mci--alzheimers-disease-300544044.html SOURCE NeuroCog Trials |